Cover Image
Market Research Report

Microneedle Drug Delivery Devices to 2024

Published by Greystone Research Associates Product code 928858
Published Content info
Delivery time: 1-2 business days
Back to Top
Microneedle Drug Delivery Devices to 2024
Published: March 17, 2020 Content info:

Microneedle technology is attaining commercial viability at a time when drug developers are faced with new challenges as they assess ways to administer new classes of compounds with significant therapeutic potential. The widespread availability of rapid throughput screening is accelerating the discovery of new drugs, a significant number of which are large-molecule therapeutic compounds that cannot tolerate passage through the digestive system, requiring pharmaceutical companies to forego oral formulations and select alternate routes of administration. Microneedle technology has the potential address the growing trend toward self-administration by allowing the precise placement of therapeutic agents at prescribed locations below the skin. To succeed, developers must refine the techniques for large-scale manufacturing and advance the design integration of microneedles into commercially viable drug delivery systems.

What Your Will Learn:

  • What approved drug products are currently supplied in microneedle devices and systems, what are the device specifics, and who markets them?
  • Who are the branded microneedle drug delivery device and system suppliers, their manufacturing infrastructure and locations, their capabilities?
  • What are the major factors that are influencing demand for microneedle drug delivery?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the essential design factors, material selection issues, technologies and market development issues for microneedle drug delivery products?
  • What are the important therapeutic markets for microneedle delivery products and what is their market share now? What will it be in 2024?
  • What are the significant economic, technology, and regulatory factors affecting the market for microneedle drug delivery systems?
Table of Contents
Product Code: MDD292F

Table of Contents

  • Executive Summary
  • Microneedles - Where we are today
  • Microneedle Demand Drivers
  • Population Demographics
  • Chronic Conditions
  • Patient Self-care
  • Managed Care Initiatives
  • Microneedle Arrays & Array Geometries
  • Microneedle Device Technology
  • Material Selection
  • pH-responsive Co-polymers
  • Fabrication Methods
  • Microforming
  • Micromachining
  • Structured Films
  • Emerging Fabrication Methods
  • Additive Manufacturing
  • InkJet Printing
  • 3D Printing
  • Electrospun Arrays
  • Electrodeposition
  • Magnetization-induced
  • Self-assembly
  • Array Architectures
  • Microneedle Form Factors
  • Solid Microneedles
  • Coated Microneedles
  • Hollow Microneedles
  • Carbon Nanotubes
  • Ion Etching
  • C-MEMS
  • Electrolyte Sensing
  • Dissolving Microneedles
  • Hydrogels
  • Stretched Needles
  • Sustained Release Microneedles
  • Silk Microneedles
  • Syringe-mounted Microneedles
  • Specialty Microneedles
  • Phase Transition
  • Composite Microneedles
  • Microprocessor-based Devices
  • Composite Microneedles
  • Light-responsive Microneedles
  • Flexible Arrays
  • Microneedles & Microfluidics
  • Wearable Microneedles
  • Microneedle Device Commercialization Factors
  • In Vitro Release Testing
  • Intended Use
  • Container Closure and Stability
  • Microneedle Development Initiatives
  • Non-Profits/NGOs
  • PATH Center of Excellence for Microarray Patch Technology
  • Gates Foundation
  • Government Initiatives
  • Government Technology Transfer Programs
  • Europe
  • Japan
  • North America
  • Academic Programs
  • United Kingdom
  • South Korea
  • Netherlands
  • Japan
  • Ireland
  • Sweden
  • Australia
  • Italy
  • Markets and Opportunities
  • Genetic/DNA/Nucleotide Therapeutics
  • nRNA
  • Imunotherapeutics
  • HIV
  • Metabolic
  • Diabetes
  • Neurology
  • Migraine
  • Osteoporosis
  • Oncology
  • Vaccines
  • Prophylactic Vaccines
  • Vaccine Dose Sparing
  • Therapeutic Peptides
  • Market Participant Profiles
Back to Top